Rapid ASPECTS receives clearance as first neuroimaging analysis device in computer-aided diagnostic category.
Advanced stroke imaging company RapidAI announced today it has secured 510(k) clearance from the U.S. Food & Drug Administration for its neuroimaging analysis device Rapid ASPECTS.
This is the first device to receive clearance in the computer-aided diagnostic software (CADx) category, and, according to a company statement, it is the only product confirmed to improve physician interpretations of non-contract CT using a standardized APSECT score. It can be particularly useful for less experienced readers, company officials said.
“The FDA’s advanced CADx clearance has never been granted to a neuroimaging solution before,” said Jim Rosa, senior vice president of regulatory and clinical at RapidAI. “Through a combination of clinically validated advances in AI and machine learning, Rapid ASPECTS offers a glimpse into the future of stroke imaging.”
Related Content: CT Predicts Stroke Patients Benefitting From Endovascular Thrombectomy
Rapid ASPECTS is based on the Alberta Stroke Program Early CT Scoring (ASPECTS) system, and it uses a validated machine-learning algorithm to identify affected regions of the brain and create an ASPECT score than can pinpoint early signs of stroke in non-contrast CT scans. In doing so, it can help providers identify areas of the brain that have irreversible injury.
Overall, according to company information, Rapid ASPECTS offers three main features:
Ultimately, company officials said, Rapid ASPECTS is designed to facilitate better patient outcomes.
“Rapid ASPECTS represents the next AI-powered step forward in stroke imaging, and the groundbreaking CADx clearance from the FDA puts it in a class by itself,” said RapidAI co-founder Greg Albers, M.D., professor of neurology at Stanford University and director of the Stanford Stroke Center. “In addition to helping stroke teams with faster triage and transfer decision, Rapid ASPECTS also improves the accuracy of typical readers.”
Rapid ASPECTS is already available internationally and will be commercially available in the United States later in July.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.
Where Things Stand with the Radiologist Shortage
June 18th 2025A new report conveys the cumulative impact of ongoing challenges with radiologist residency positions, reimbursement, post-COVID-19 attrition rates and the aging of the population upon the persistent shortage of radiologists in the United States.